Merck, Ridgeback Announce Trial Results For Antiviral Medication

The video discusses a new COVID-19 pill that reduces hospitalization or death risk by 50% in trials. It highlights the importance of early treatment and the government's plan to purchase 1.7 million doses. The pill works by hindering virus multiplication, making it harder for the virus to spread. It complements existing treatments like vaccines and monoclonal antibodies. The company aims to produce 10 million treatment courses by year-end.

What was the reduction in risk of hospitalization or death in the phase three trial of the antiviral pill?

• 75%

• 50%

• 100%

• 25%

Who has been briefed about the new antiviral pill?

• The White House COVID response team

• The World Health Organization

• The European Medicines Agency

• The CDC

How does the antiviral pill work against COVID-19?

• By boosting the immune system

• By reducing inflammation

• By interfering with the virus's multiplication

• By increasing antibody production

What is the role of the new antiviral pill in COVID-19 treatment?

• It replaces vaccines

• It is a standalone treatment

• It complements existing treatments

• It is only for severe cases

How many courses of treatment does the company plan to produce by the end of the year?

• 5 million

• 1 million

• 10 million

• 20 million